Nachrichten zur Vertex Pharmaceuticals Inc. Aktie

Whats going on with CRISPR Therapeutics (NASDAQ: CRSP)? The companys shares have been southbound for the better part of three…

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this years biotech winners, with the shares climbing 27%…

San Francisco (www.aktiencheck.de) - Rating-Update: Die Analysten von Wells Fargo Advisors stufen die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN:…

Santa Claus will soon be on his way delivering presents to kids around the world. But could the jolly gift-giver…

Shares of the medical-device maker DexCom (NASDAQ: DXCM) are down by 37% this year. The diabetes-focused healthcare company disappointed investors…

New York (www.aktiencheck.de) - Rating-Update: Andrew Fein, Analyst H.C. Wainwright & Co., bewertet die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003,…

Its that time of year again. Im not referring to buying gifts and preparing holiday meals -- although that may…

CRISPR Therapeutics (NASDAQ: CRSP) isnt a stock thats wanting for reasons to invest. Between the solid launch of its first…

FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO),…

New York (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von Oppenheimer: Oppenheimer hat die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN: 882807, Ticker-Symbol:…

London (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von Barclays: Aktuelle Bewertung Die britische Investmentbank Barclays hat das Kursziel für Vertex Pharmaceuticals Inc. (ISIN: US92532F1003,…

Charlotte (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von BofA Securities: Aktuelle Bewertung BofA Securities hat ihr Kursziel für die Aktie von Vertex Pharmaceuticals Inc.…

Toronto (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von RBC Capital Markets: Aktuelle Bewertung RBC Capital-Analyst, Brian Abrahams, hat das Kursziel für Vertex Pharmaceuticals Inc.…

Block & Leviton is investigating Vertex Pharmaceuticals (Nasdaq: VRTX) for potential securities fraud. Investors who lost money should contact the…

What do Apple (NASDAQ: AAPL) and Vertex Pharmaceuticals (NASDAQ: VRTX) have in common? At first glance, not much. The former…

Investors looking for stocks that can make dramatic gains can find some in the biopharmaceutical industry. Right now, there are…

Gilead, Eli Lilly, Vertex Pharmaceuticals and AbbVie have outperformed the industry this year and are likely to see continued momentum…

St. Louis (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von Stifel: 1. Hintergrund der Einschätzung zur Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN:…

Pharmaceutical and biotech stocks often are seen as steady and safe options for investors for one particular reason. Patients need…

Some stocks sizzle, then fizzle. Others, though, build long-lasting momentum thanks to strong underlying business fundamentals. Three Motley Fool contributors…

Investing in biotech stocks isnt for everyone because the very nature of their business is fraught with risk. As a…

…

Nishant Pant breaks down a bull call spread trade in Vertex Pharmaceuticals.…

New York (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von Jefferies & Co: Rating und Kursziel Jefferies hat die Aktie von Vertex Pharmaceuticals Inc. (ISIN:…

I think the stock markets valuation has become frothy. And Im in good company; Warren Buffetts actions show that he…

The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark,…

Growth. Its what most investors want more than anything else from their stocks. Some stocks can deliver more of it…

Things arent getting much better for Pfizer (NYSE: PFE). The company is still suffering from the significant drop in sales…

Its getting harder these days to find great growth stocks trading for less than $100 a share. It almost seems…

Kulmbach (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von "Der Aktionär": Jürgen Dreifürst vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie…

Die amerikanische Investmentbank JPMorgan hat sich über die Aussichten der Pharmabranche im Jahr 2025 geäußert und ist insbesondere für Vertex…

Die amerikanische Investmentbank JPMorgan hat sich über die Aussichten der Pharmabranche im Jahr 2025 geäußert und ist insbesondere für Vertex…

Its been a great couple of years for the stock market. From the end of 2022 through Nov. 29, the…

Ark Invest chief Cathie Wood is known for scooping up shares of innovators early in their growth stories and holding…

What you do in the present makes a huge difference in how successful youll be in the future. This is…

On Nov. 21, shares of CRISPR Therapeutics (NASDAQ: CRSP) were down 47% from a peak they reached in March. This…

Godzilla and King Kong surely werent born big. They began small and grew over time to their gargantuan sizes even…

Investing can sometimes require a significant amount of upfront cash. For example, you might need a lot of capital to…

Many investors have a type of acrophobia (the fear of heights). Its not that theyre worried about standing at the…

Biotechs often need several years to realize their visions, even after they have a drug approved for the first time.…

New York (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von der Citigroup: Aktuelle Bewertung Citi hat die Coverage von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN:…

San Francisco (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von JMP Securities: 1. Erhöhung des Kursziels auf 61 USD: JMP Securities hat das Kursziel…

Vancouver (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von Canaccord Genuity: Rating und Kursziel Canaccord Genuity vergibt weiterhin ein "sell"-Rating für die Aktie von Vertex…

Toronto (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von Scotiabank: Rating und Kursziel Scotiabank vergibt weiterhin ein "sector perform"-Rating für die Aktie von Vertex Pharmaceuticals…

New York (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von Morgan Stanley: Aktuelle Bewertung Morgan Stanley hat das Kursziel für Vertex Pharmaceuticals Inc. (ISIN: US92532F1003,…

Toronto (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von RBC Capital Markets: 1. Überblick über die Kurszielanpassung und Empfehlung RBC Capital Markets hat das Kursziel…

New York (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von Sanford C. Bernstein & Co: Aktuelle Bewertung Bernstein hat das Kursziel für Vertex Pharmaceuticals Inc.…

Grund zur Freude haben Aktionäre von Vertex Pharmaceuticals : Der Titel verteuert sich am Dienstag deutlich. Zu den Gewinnern an…

VRTX earnings call for the period ending September 30, 2024.…

…